Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignant gastrointestinal stromal tumor~  * Potentially resectable primary disease~ * Potentially resectable recurrent disease~    * Local or intra-abdominal/pelvic metastatic disease~* Documented c-kit (CD117) expression by immunohistochemical analysis of either initial core specimen or, if recurrent disease, from original tumor block~* Primary disease must be visceral, intra-abdominal, or pelvic in origin~* At least 1 unidimensionally measurable lesion~  * At least 5 cm for primary disease~ * At least 2 cm for recurrent disease~* At least 1 viable core biopsy tumor specimen obtained within 8 weeks before registration~* Performance status - Zubrod 0-2~* WBC at least 3,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* ALT/AST no greater than 2.5 times ULN~* No uncontrolled chronic liver disease~* Creatinine no greater than 1.5 times ULN~* No uncontrolled chronic renal disease~* No New York Heart Association class III or IV cardiac disease~* Must be able to lie still in the PET scanner for approximately 1-2 hours~* No uncontrollable hyperglycemia~* No medical or psychological condition that would preclude study participation~* No severe or uncontrolled medical disease~* No active uncontrolled infection~* No known or suspected hypersensitivity to any component of the study drug~* Any prior malignancy is allowed provided patient remains disease free from that malignancy~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 3 months after study participation~* At least 28 days since prior biologic therapy~* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)~* At least 28 days since prior chemotherapy~* At least 28 days since prior radiotherapy~* See Disease Characteristics~* At least 28 days since prior investigational drugs~* At least 28 days since prior imatinib mesylate~* No concurrent therapeutic doses of warfarin~* Concurrent low-molecular weight heparin or mini-dose warfarin (1 mg per day) prophylaxis is allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).